Kornimate/medical-research-clean huggingface dataset:
dual-echo and inversion recovery magnetic resonance imaging pulse sequences in diagnosis of temporomandibular disorders. diagnostic accuracy study

Conditions: Temporomandibular Joint Disorders

Summary: in the present study, investigators are going to investigate the potential of inversion recovery (fluid attenuated inversion recovery -flair and short-ti inversion recovery -stir) sequence images to demonstrate joint effusion, compared to t2-weighted images.


Eligibility criteria:
inclusion criteria: * patients with pain related to temporomandibular joint. * patients with limited mouth opening. exclusion criteria: * patients with pain related to temporomandibular joint for less than one month duration. * patients with limited mouth opening for less than one month duration. * patients with history of tmj surgical intervention. * patients with history of tmj arthrocentesis.
safety, tolerability, and pharmacokinetics study of human monoclonal antibody brii-196

Conditions: COVID-19

Summary: this is a phase 1 study in which healthy adult volunteers will receive brii-196 or placebo and will be assessed for safety, tolerability, and pharmacokinetics.


Eligibility criteria:
inclusion criteria: * subject must be 18 to 49 years of age inclusive; * body weight ≤100 kg and body mass index (bmi) within the range of 19.0-24.0kg/m2 (inclusive); * male or female; exclusion criteria: * any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation; * a history of significant hypersensitivity, intolerance, or allergy to any drug compound; * history of alcohol or other substance abuse;

Keywords: covid-19 phase i monoclonal antibody
bleeding in critically ill children with underlying oncologic diagnoses

Conditions: Cancer; Bleeding

Summary: "bleeding in critically ill children with underlying oncologic diagnoses ," will be a prospective observational cohort study looking at the epidemiology of bleeding in the pediatric icu population at msk.


Eligibility criteria:
inclusion criteria: * all children (≥28 days old through 18 years of age) with an oncologic diagnosis admitted to the picu at memorial sloan kettering cancer center * an oncologic diagnosis will include those with a cancer diagnosis or those being treated at msk for blood disorders, immunodeficiencies and complications of transplant. exclusion criteria: * preterm infants (\<44 weeks gestation at age of enrollment) as in these patients most bleeding etiologies are specific to the neonatal period and the bleeding assessment tool is not calibrated for this population * known limitation of care at enrollment (standing do not resuscitate order), as the interventions and clinical outcome would be biased * pre-existing bleeding disorders

Keywords: critically ill children 19-407
impact of preoperative vfa on intraoperative adverse events in patients undergoing laparoscopic radical gastrectomy

Conditions: Gastric Cancer

Summary: preoperative visceral fat area (vfa) is associated with an increased incidence of postoperative complications in gastric cancer (gc). however, the relationship between vfa and intraoperative adverse events (iaes) remains unclear. therefore, this study aimed to evaluate the impact of preoperative vfa on iaes in patients undergoing laparoscopic radical gastrectomy for gc, using data from two prospective trials. simultaneously, a predictive model for iaes was constructed to provide a basis for the early identification of high-risk populations and the implementation of personalized perioperative management measures.

a post hoc analysis was performed using data from two previous prospective studies (\[nct02327481\] and \[nct01609309\]). the patients were divided into high- and low-vfa groups. all iaes were reviewed from the surgical videos and graded using classintra. logistic regression analyses were used for the construction of nomograms as predictive models.

Eligibility criteria:
inclusion criteria: this study comprised two prospective trials conducted at fujian medical university union hospital (fmuuh): the fuges-001 study (clinicaltrials.gov, nct02327481) and a subset of the class-01 multicenter study (clinicaltrials.gov, nct01609309) exclusion criteria: 1. open surgery; 2. non-adenocarcinoma gastric cancers 3. palliative surgery 4. exploratory operation 5. ct data missing

Keywords: gastric cancer intraoperative adverse events complications visceral fat area laparoscopic surgery
functional mri evaluation of the effect of citalopram in autism spectrum disorders

Conditions: Autism Spectrum Disorders

Summary: the purpose of this proof of concept study is to use functional magnetic resonance imaging and behavioral assessments to investigate the effect of citalopram on restricted repetitive behaviors in people with autism spectrum disorders.


Eligibility criteria:
inclusion criteria: * ambulatory status (outpatient) at time of consent * age 10-55 years * clinical diagnosis of autism spectrum disorder * iq greater than or equal to 70 * score greater than 8 on children's yale-brown obsessive compulsive scale * free of psychoactive medication for at least: one month for fluoxetine; two weeks for other ssris and neuroleptics; and five days for stimulants prior to mri scanning \[excepting stable doses (greater than three months duration) of anticonvulsant medication for seizure disorder\] exclusion criteria: * age less than 10 years or greater than 55 years, at time of consent * estimated iq \< 70 * uncontrolled epilepsy (seizure within 6 months prior to consent) * 4. presence of medical conditions that might interfere with participation, or where participation would be contraindicated * history of neurological injury: head trauma, poorly-controlled seizure disorder (seizure within the preceding six months), stroke, prior neurosurgery, or under the care of a neurologist or neurosurgeon as determined by interview * history of claustrophobia * implanted or irremovable metal in the body (including certain tattoos and permanent make-up) * current pregnancy (as verified by testing prior to both initial dose administration of citalopram or placebo and prior to magnetic resonance imaging) due to the risk that may be associated with ssri treatment and magnetic resonance imaging on fetal health * medical contraindications to ssri therapy as determined by history (including induction of mania or hypomania during ssri therapy, or known drug allergy) * concomitant medication that would interfere with study participation * prior history of citalopram treatment failure at appropriate doses and duration * prior history of treatment failure to two previous ssri trials at appropriate doses and duration * ongoing need for psychoactive medication other than study medication \[excepting stable doses (greater than three months duration) of anticonvulsant medication for seizure disorder, or diphenhydramine (benadryl®)for sleep\]

Keywords: restricted repetitive behaviors restricted interests aspergers autism
prospective validation of 3d dose metrics as selection criteria for adaptive radiotherapy in breast cancer patients

Conditions: Breast Cancer

Summary: in a retrospective study the investigators defined quantitative action levels based on dose and volume measures for adaptive radiation therapy in breast cancer patients (zegers et al. acta oncol 2017). the aim of this study is to validate these parameters in a prospective study.

during radiotherapy, changes in patient anatomy or positioning can result into differences in dose deposition, which is the main factor influencing tumor control or side-effects. dose-guided radiation therapy is the systematic evaluation of the dose delivery during treatment for an individual patient with the aim to adapt the treatment if needed. recalculation of the dose during treatment can be performed using the imaging information during treatment. in a retrospective study the investigators defined quantitative action levels based on dose and volume measures for adaptive radiation therapy in breast cancer patients (zegers et al. acta oncol 2017). the aim of this study is to validate these parameters in a prospective study.

Eligibility criteria:
inclusion criteria: * breast cancer patients * planned for external beam radiation treatment. * whole breast irradiation or simultaneous integrated boost

Keywords: dose-guided radiation therapy cbct
study of febrile illness for dengue-endemic areas in latin america

Conditions: Dengue Fever; Fever

Summary: the purpose of this study is to detect acute febrile episodes and dengue infection in five latin american countries to assess dengue seroprevalence. primary objectives: * to identify acute febrile episodes among the cohort in order to detect the presence of dengue infection. * to describe the dengue seroprevalence among the cohort at baseline and at the end of the study.

all participants will make two visits to a study site, an enrollment visit and a termination visit. additional visits will be made if febrile episodes occur: an acute visit and a convalescent visit. participants or their parents/guardians will be contacted weekly to monitor the occurrence of febrile episodes and ensure appropriate assessment and care. no vaccine will be provided or administered in this study

Eligibility criteria:
inclusion criteria : * aged 9 to 16 years on the day of inclusion and resident of the site zone * participant in good health, based on medical history and physical examination * assent form has been signed and dated by the participant (if required by local regulations), and informed consent form has been signed and dated by the parent(s) or another legally acceptable representative (and by the participant and/or an independent witness if required by local regulations) * participant able to attend all scheduled visits and to comply with all study procedures exclusion criteria : * participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding enrollment * planned participation in another clinical trial during the present study period * known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroids therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) * self-reported seropositivity for human immunodeficiency virus (hiv) infection * chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion * current alcohol abuse or drug addiction that may interfere with the participant's ability to comply with study procedures * receipt of blood or blood-derived products in the past 3 months * receipt of any vaccine in the 4 weeks preceding the day of enrollment except for pandemic influenza vaccination, which may be received at least 2 weeks before enrollment * planned receipt of any vaccine in the 4 weeks following enrollment * deprived of freedom by administrative or court order, or in an emergency setting, or hospitalized involuntarily * identified as employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the investigator.

Keywords: dengue fever fever seroprevalence
study evaluating oral moa-728 for the treatment of opioid-induced bowel dysfunction (oibd) in subjects with chronic non-malignant pain

Conditions: Constipation

Summary: the primary purpose of the protocol is to evaluate the safety, efficacy, and tolerability of moa-728 in subjects with opioid-induced bowel dysfunction (oibd) with associated chronic non-malignant pain.


Eligibility criteria:
inclusion criteria: * adult outpatients with opioid-induced bowel dysfunction and chronic non-malignant pain. * taking oral, transdermal, intravenous, or subcutaneous opioids. * willingness to discontinue all pre-study laxative therapy and utilize only study permitted rescue laxatives. exclusion criteria: * history of chronic constipation before the initiation of opioid therapy. * other gi disorders known to affect bowel transit. * women who are pregnant, breast-feeding, or plan to become pregnant.

Keywords: oibd oic opioid constipation laxative
lifestyle intervention for diabetes and weight management in psychosis

Conditions: Type 2 Diabetes Mellitus; Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder; Bipolar I Disorder; Substance-induced Psychosis; Psychotic Disorders; Major Depressive Disorder

Summary: the rate of type-2 diabetes mellitus (t2dm) is at least 2-3 times higher in persons with psychotic illnesses than in the general population. life expectancy of individuals with psychosis is also 20-25 years less than the general population, primarily due to premature onset of cardiovascular disease (cvd). despite the high risk for t2dm and cvd, psychotic illness has been an exclusion criterion in all large-scale studies of diabetes prevention and management. we propose a 3-year randomized controlled trial examining the effectiveness of a lifestyle intervention (li) aimed at reducing caloric intake and increasing physical activity in overweight or obese individuals (n=150) suffering from both a psychotic illness and t2dm. weight and glycemic control will be the primary outcome variables. it is hypothesized that a significant weight reduction and improvement in glycemic control will be found in those who receive the li relative to those who do not.


Eligibility criteria:
inclusion criteria: 1. between the ages of 18 and 70 years (inclusive) 2. dsm-iv-tr diagnosis of one of the psychotic disorders listed above 3. body mass index (bmi) \> 25 kg/m2 at the time of enrollment 4. clearly documented diagnosis of type-2 diabetes mellitus or prediabetes 5. ability to provide informed consent 6. no medical contraindication to participation in weight reduction / exercise program, determined in consultation with their primary care physician 7. female participants, of childbearing potential, using a medically accepted means of contraception exclusion criteria: 1. inability to give informed consent 2. currently enrolled in a formal structured weight management program 3. currently being prescribed medication specifically for weight loss 4. participants with unstable or active cardiovascular illnesses (myocardial infarction, chf, etc), active or end-stage renal disease, unstable thyroid disease, etc. 5. recurrent episodes of diabetic ketoacidosis, seizure or coma without warning or severe hypoglycemia
multi-parametric mri in patients suspected for muscle invasive bladder cancer: a new local staging paradigm

Conditions: Bladder Cancer

Summary: a two-arm multicenter randomised controlled trial, comparing progression free survival, time to definitive treatment and cost-effectiveness of the standard of care (turbt) and mpmri followed by same-day cystoscopic bladder biopsy for diagnosis of patients with suspicion of muscle-invasive bladder cancer.


Eligibility criteria:
inclusion criteria: * patients (18+ years of age) with clinically suspected mibc, without lymph node or distant metastases, written informed consent exclusion criteria: * unable or unwilling to undergo mpmri * unfit for turbt * unfit for definitive treatment with curative intent * a history of cancer, including bladder cancer, except non-melanoma skin cancer or prostate cancer on active surveillance

Keywords: mpmri + same-day biopsy turbt
added value of pet/ct in assessment of hepatocellular malignancy post radiofrequency ablation

Conditions: PET/CT; Hepatocellular Malignancy; Radiofrequency Ablation

Summary: this study aims to assess the residual tumoral activity versus the well ablation of اepatocellular carcinoma (hcc) post radiofrequency ablation.

hepatocellular carcinoma (hcc) is the most common primary liver malignancy and is a leading cause of cancer-related death worldwide. it is the third most common cause of death of cancer worldwide, also the sixth and fourth common cancer in worldwide and egypt, respectively. radiofrequency ablation (rfa) is a technique that is recently developed for the ablation of liver tumours. it converts radio frequency waves into thermal energy, causing coagulation necrosis of the tumours. it has attracted great interest in recent years because of the excellent response rate with little morbidity. compared with other local ablative modalities, rfa has been shown to be safer and more effective. positron emission tomography (pet) with 18f-fluoro-2- deoxy-d-glucose (18f-fdg) is a functional imaging tool that provides metabolic information of the lesion. it is effective for diagnosis, monitoring therapy and detection of recurrent tumours of various cancers because of its high sensitivity and specificity. however, it is less successful in the detection of primary hcc because of variable uptake. even though the value of 18f-fdg pet for the detection of primary hcc remains controversial, 18f-fdg pet would seem to be appropriate for the follow-up of liver tumours.

Eligibility criteria:
inclusion criteria: * age from 40 to 75 years. * both sexes. * patients with hepatocellular carcinoma (hcc) and underwent radiofrequency ablation (rfa) . exclusion criteria: * patients with past history of contrast allergy. * patients with blood glucose level \>200 mg/dl at the time of the study. * high serum creatinine\> 2 mg / dl. * small lesions \< 10 mm. * well differentiated hepatocellular carcinoma (hcc) lesions by pathology.
transcranial direct current stimulation to enhance cognition in mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: the study will examine whether the effects of computerized brain training are enhanced when training is combined with mild brain stimulation in patients with mild cognitive impairment. we hypothesize that this combination will produce greater improvements in cognitive functioning than computerized brain training alone.


Eligibility criteria:
inclusion criteria: * aged 60 - 85 years. * meet diagnostic criteria for amnestic mild cognitive impairment. exclusion criteria: * inability to provide informed consent. * concurrent medication likely to affect mental performance. * current substance use or dependence in last 3 months. * current active psychiatric or neurological condition
role of stem cell therapy in interstitial pulmonary fibrosis

Conditions: Stem Cell Transplant Complications

Summary: currently, the application status of mscs as treatment modalities in ipf is still in its infancy and remains exploratory. although a number of safety and efficacy clinical trials of mscs as therapeutic options in immune-mediated and cardiac diseases have already been published with tantalizing results, to our disappointment, pulmonary and critical care medicine have traditionally lagged behind other therapeutic and research fields including hematology, gastroenterology and cardiology in translational studies of the use of reparative cells


Eligibility criteria:
inclusion criteria: * age 18 to 75 years (both inclusive) * high-resolution computed tomography (hrct) scan that is very suggestive or consistent with a probable diagnosis of usual interstitial pneumonia. * bronchoalveolar lavage must be performed at any time before inclusion and must have failed to show features supporting alternative diagnoses. * the duration of the disease should be more than three months, and bibasilar inspiratory crackles should be present. * dyspnea score of at least 2 on a scale of 0 (minimum) to 10 (maximum). * fvc \> 50% of the predicted normal value and dlco \> 35% of the predicted value. * patients under treatment with n-acetylcysteine or pirfenidone should discontinue drug and enter a wash-out period for at least 6 weeks prior study enrolment. exclusion criteria: * fvc \< 50% predicted normal value and dlco \< 35%predicted normal value. * lung cancer or with an evidence of active malignancyfor at least 5 years. * uncontrolled heart failure. * renal failure * hepatic failure, * neurological abnormalities including stroke and myasthenia gravis * anti-coagulants therapy. * active infections.

Keywords: stem cell therapy ipf
comparison of anti-ischemic drug therapy and percutaneous transluminal angioplasty after myocardial infarction

Conditions: Myocardial Ischemia

Summary: silent ischemia has been shown to negatively affect prognosis in patients after myocardial infarction. however, long-term outcome data in totally asymptomatic patients is missing and it is unknown whether angioplasty in addition to secondary preventive measures is superior to antiischemic drug therapy in these patients. therefore, the swissi 2 study was started 15 years ago with the aim of comparing the effects of angioplasty with medical therapy on long-term outcome in patients with recent myocardial infarction and silent ischemia.

silent ischemia has been shown to negatively affect prognosis in patients after myocardial infarction (mi). despite these consistent findings, there are almost no prospective data unequivocally documenting a benefit of antiischemic therapy on prognosis in patients with silent ischemia. there is some indirect evidence of a better outcome after repeat angioplasty for silent restenosis. in patients with a recent mi, the asymptomatic cardiac ischemia pilot study documented a short-term benefit of antiischemic drug therapy and angioplasty in patients with silent and symptomatic ischemic episodes. however, long-term outcome data in totally asymptomatic patients is missing and it is unknown whether angioplasty in addition to secondary preventive measures is superior to antiischemic drug therapy in these patients. therefore, the (swissi 2) study was started 15 years ago with the aim of comparing the effects of angioplasty with medical therapy, each combined with secondary preventive advice, aspirin and statin therapy, on long-term outcome in patients with recent mi and an exercise test without symptoms but silent ischemia verified by stress imaging.

Eligibility criteria:
inclusion criteria: * recent myocardial infarction within last 3 months * documented silent myocardial ischemia (type i) exclusion criteria: * symptomatic myocardial ischemia

Keywords: myocardial ischemia randomized controlled trials angioplasty, transluminal, percutaneous coronary drug therapy
an epidemiological study aimed to record standard daily practice in managing patients with hypercholesterolemia

Conditions: Hypercholesterolemia

Summary: this study is aimed to collect the following serbia-specific epidemiology data on hypercholesterolemia: patents characteristics, patients' management/treatment and physicians' standard practice. in addition, the aim is to determine the proportion of patients on lipid-lowering pharmacological treatment who have reached the ldl-c and hdl-c treatment goals.


Eligibility criteria:
inclusion criteria: * patients with hypercholesterolemia currently receiving a lipid lowering agent exclusion criteria: * pregnancy and lactation.

Keywords: standard daily practice in managing patients with hypercholesterolemia